SCHEMBL3548045

SCHEMBL3548045

CC(=O)Nc1ccc(-c2c(C#N)c(N)nc(OCc3ccccc3)c2C#N)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 1/20 0.56
ADORA2A P29274 1/20 0.56
ADORA2B P29275 1/20 0.56
GHSR Q92847 6/20 0.55
ADORA1 P30542 3/20 0.54
PDE5A O76074 1/20 0.47
PDE1A P54750 1/20 0.47
PDE1B Q01064 1/20 0.47
PDE1C Q14123 1/20 0.47
ALDH1A1 P00352 2/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
KDM4E B2RXH2 1/20 0.45
MAPT P10636 1/20 0.45
HPGD P15428 1/20 0.45
CASP1 P29466 1/20 0.45
CASP7 P55210 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
HSD17B10 Q99714 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3554945 0.90 ADORA2A (0.52) ADORA3ADORA2AADORA2BGHSRADORA1
SCHEMBL13914389 0.80 ADORA2A (0.73) ADORA3ADORA2AADORA2BADORA1PDE5A
SCHEMBL3359530 0.78 ADORA1 (0.63) ADORA2AADORA2BADORA1ELAVL1SQOR
SCHEMBL3356574 0.78 ADORA1 (0.61) ADORA3ADORA2AADORA1MEN1KMT2A
SCHEMBL3550981 0.77 ADORA1 (0.60) ADORA3ADORA2AADORA2BADORA1ALDH1A1
SCHEMBL7013023 0.77 ADORA3 (0.65) ADORA3ADORA2AADORA2BGHSRADORA1
SCHEMBL7014230 0.76 ALDH1A1 (0.61) ADORA3ADORA2AADORA2BADORA1PDE5A
SCHEMBL26632998 0.76 SQOR (0.57) ADORA2AADORA1ALDH1A1MEN1KMT2A
SCHEMBL3556602 0.76 ADORA2B (0.68) ADORA3ADORA2AADORA2BADORA1PDE5A
SCHEMBL4306407 0.76 ADORA3 (0.64) ADORA3ADORA2AADORA2BGHSRADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7855219-B2 Substituted 2-oxy-3,5-dicyano-4aryl-6-aminopyridines and use thereof BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-12-21 US disclosed
US-7855219-B2 Substituted 2-oxy-3,5-dicyano-4aryl-6-aminopyridines and use thereof BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-12-21 US disclosed
US-7855219-B2 Substituted 2-oxy-3,5-dicyano-4aryl-6-aminopyridines and use thereof BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-12-21 US disclosed
US-20050261502-A1 Substituted 2-oxy-3,5-dicyano-4-aryl-6-aminopyridines and use thereof BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2005-11-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050261502-A1 Substituted 2-oxy-3,5-dicyano-4-aryl-6-aminopyridines and use thereof ADORA2A, ADORA3, ADORA1 ADORA3 2/4885ADORA2A 1/4885ADORA2B 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.